Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice

International Immunopharmacology

Volumn 7, Issue 7, 2007, Pages 920-927

  Hashemi, Seyed Mahmoud ^a   Hassan, Zuhair M ^a   Soudi, Sara ^a   Ghazanfari, Tooba ^b   Kheirandish, Maryam ^c   Shahabi, Shahram ^d  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^d URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer immunotherapy; Fibrosarcoma; Heat shock proteins; HSP 70; Tumor cell lysate

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; FIBROSARCOMA; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; VACCINATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL EXTRACTS; FEMALE; FIBROSARCOMA; HSP70 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 34247849277     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.02.013     Document Type: Article

References (31)

1. Chen C.H., and Wu T.C. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 5 (1998) 231-252
2. Gething M.J., and Sambrook J. Protein folding in the cell. Nature 355 (1992) 33-45
3. Srivastava P.K., and Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 6 (1994) 728-732
4. Wang X.Y., Manjili M.H., Park J., Chen X., Repasky E., and Subjeck J.R. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 32 (2004) 13-20
5. Tamura Y., Peng P., Liu K., Daou M., and Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 (1997) 117-120
6. Arnold-Schild D., Hanau D., Spehner D., Schmid C., Rammensee H.G., de la Salle H., et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 162 (1999) 3757-3760
7. Binder R.J., Anderson K.M., Basu S., and Srivastava P.K. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol 165 (2000) 6029-6035
8. Basu S., Binder R.J., Ramalingam T., and Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14 (2001) 303-313
9. Basu S., and Srivastava P.K. Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 5 (2000) 443-451
10. Basu S., Binder R.J., Suto R., Anderson K.M., and Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12 (2000) 1539-1546
11. Srivastava P.K., DeLeo A.B., and Old L.J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A 83 (1986) 3407-3411
12. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20 (2002) 395-425
13. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20 (2002) 4169-4180
14. Todryk S., Melcher A.A., Hardwick N., Linardakis E., Bateman A., Colombo M.P., et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163 (1999) 1398-1408
15. Ito A., Shinkai M., Honda H., and Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 8 (2001) 649-654
16. Todryk S.M., Eaton J., Birchall L., Greenhalgh R., Soars D., Dalgleish A.G., et al. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunol Immunother 53 (2004) 323-330
17. Castelli C., Ciupitu A.M., Rini F., Rivoltini L., Mazzocchi A., Kiessling R., et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61 (2001) 222-227
18. Panthel K., Meinel K.M., Sevil Domenech V.E., Geginat G., Linkemann K., Busch D.H., et al. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 8 (2006) 2539-2546
19. Zeng Y., Feng H., Graner M.W., and Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101 (2003) 4485-4491
20. Kim H.S., Choo Y.S., Koo T., Bang S., Oh T.Y., Wen J., et al. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett 103 (2006) 142-148
21. Schnurr M., Galambos P., Scholz C., Then F., Dauer M., Endres S., et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61 (2001) 6445-6450
22. Hassan Z.M., Yaraee R., Zare N., Ghazanfari T., Sarraf Nejad A.H., and Nazori B. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Int Immunopharmacol 3 (2003) 1483-1489
23. Hassan Z.M., Feyzi R., Sheikhian A., Bargahi A., Mostafaie A., Mansouri K., et al. Low molecular weight fraction of shark cartilage can modulate immune responses and abolish angiogenesis. Int Immunopharmacol 5 (2005) 961-970
24. Moingeon P. Cancer vaccines. Vaccine 19 (2001) 1305-1326
25. Ribas A., Butterfield L.H., Glaspy J.A., and Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21 (2003) 2415-2432
26. Forsdyke D.R. Heat shock proteins as mediators of aggregation-induced 'danger' signals: implications of the slow evolutionary fine-tuning of sequences for the antigenicity of cancer cells. Cell Stress Chaperones 4 (1999) 205-210
27. Wang X.Y., Kazim L., Repasky E.A., and Subjeck J.R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 166 (2001) 490-497
28. Wang X.Y., Kaneko Y., Repasky E., and Subjeck J.R. Heat shock proteins and cancer immunotherapy. Immunol Invest 29 (2000) 131-137
29. Schueller G., Stift A., Friedl J., Dubsky P., Bachleitner-Hofmann T., Benkoe T., et al. Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells. Int J Oncol 22 (2003) 1397-1402
30. Calderwood S.K., Theriault J.R., and Gong J. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol 35 (2005) 2518-2527
31. Barth Jr. R.J., Mule J.J., Spiess P.J., and Rosenberg S.A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173 (1991) 647-658